Wedbush Brokers Reduce Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for Biogen in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.51 for the quarter, down from their prior forecast of $3.82. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $17.02 EPS and FY2027 earnings at $17.83 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Several other research analysts also recently commented on BIIB. Morgan Stanley reduced their price objective on Biogen from $157.00 to $152.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. The Goldman Sachs Group decreased their price target on Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Sanford C. Bernstein started coverage on shares of Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price objective on the stock. Canaccord Genuity Group cut their price target on shares of Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Finally, Piper Sandler reissued a “neutral” rating and issued a $135.00 price objective (down previously from $138.00) on shares of Biogen in a report on Tuesday, February 18th. Eighteen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Biogen presently has an average rating of “Hold” and a consensus price target of $213.15.

Biogen Trading Up 2.9 %

NASDAQ BIIB opened at $118.61 on Thursday. The stock has a market cap of $17.36 billion, a PE ratio of 10.60, a PEG ratio of 1.51 and a beta of 0.06. The company’s 50-day moving average price is $134.71 and its 200-day moving average price is $152.19. Biogen has a 12 month low of $110.04 and a 12 month high of $238.00. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27.

Insider Transactions at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BIIB. Lee Danner & Bass Inc. purchased a new stake in Biogen in the fourth quarter valued at $25,000. Larson Financial Group LLC boosted its stake in Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after buying an additional 141 shares during the period. Colonial Trust Co SC lifted its holdings in shares of Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 186 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in Biogen in the first quarter valued at approximately $26,000. Finally, SRS Capital Advisors Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at $33,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.